InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
4
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-65.3%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Neil Garry Arthur. Officer active across 4 companies, notably Cerecor Inc.. In total, 11 filings have been logged. Breakdown: 4 buys · 0 sell. Total volume traded: €34k. History available since 10 June 2021. The latest transaction was filed on 21 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Neil Garry Arthur
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
100,200 shares0Common StockSEC:0001586785-26-000006:0
64,866 sharesCommon StockSEC:0001586785-26-000004:0
21,892 shares@ US$13.890.078% mcap60.4% of flowCommon StockSEC:0001586785-26-000004:1
64,867 sharesCommon StockSEC:0001578563-25-000197:0
17,787 shares@ US$8.4631.9% of flowCommon StockSEC:0001578563-25-000197:1
4,000 shares@ US$3.422.9% of flowCommon StockSEC:0001628280-23-021958:0
Canonical exit: 7 Sept 2023 (T+90)
2,083 shares@ US$4.422.0% of flowCommon StockSEC:0001628280-22-031725:0
Canonical exit: 9 Mar 2023 (T+90)
8,150 sharesCommon StockSEC:0001628280-22-005912:0
4,267 shares@ US$1.571.4% of flowCommon StockSEC:0001879785-21-000037:0
Canonical exit: 10 Mar 2022 (T+90)
3,067 shares0Common StockSEC:0001628280-21-012275:0
3,692 shares@ US$2.28100.0% of flowCommon StockSEC:0001192482-21-000501:0
Canonical exit: 8 Sept 2021 (T+90)
11 of 11 declarations
About Neil Garry Arthur
NEIL GARRY ARTHUR is a declarant linked to Avalo Therapeutics, Inc., Arena Pharmaceuticals INC and Cerecor Inc., with 11 filings in total. Across the 11 sampled recent filings, buy transactions total 34253 EUR, sell transactions are 0, and the period runs from 2021-06-14 to 2026-05-26.
